Anavex Life Sciences Corp - Blarcamesine Slows Clinical Progression by 36.3% Over 48 Weeks
Anavex Life Sciences Corp - Blarcamesine在48周內將臨床進展減緩了36.3%
Anavex Life Sciences Corp - Blarcamesine Slows Clinical Progression by 36.3% Over 48 Weeks
Anavex Life Sciences Corp - Blarcamesine在48周內將臨床進展減緩了36.3%
譯文內容由第三人軟體翻譯。